Estimation of minimally important differences in EQ-5D utility and VAS scores in cancer.

Pickard AS, Neary MP, Cella D. · 2007

Read Estimation of minimally important differences in EQ-5D utility and VAS scores in cancer. by Pickard AS, Neary MP, Cella D. (2007) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/europmc-pmc2248572.txt.

Introduction

Pickard, Neary and Cella estimated minimally important differences in 2007 for the EQ-5D quality-of-life measure in cancer patients. A minimally important difference is the smallest score change patients actually notice as meaningful. Without it, trial results are hard to interpret. The team analysed data from 534 cancer patients, including 50 with lung cancer. They used anchor-based methods tied to performance status and quality-of-life groupings, plus distribution-based statistics.

For the United Kingdom utility index, important differences ranged from 0.10 to 0.12 by performance status across all cancers. The lower estimates sat nearer the true threshold, in the authors' judgement, at about 0.08 on that index. The United States index gave lower values, from 0.07 to 0.09, for the same patient groups. Visual scale estimates ranged from 8 to 12 points. Lung cancer estimates closely matched the all-cancer figures.

Catalog record

CREATORPickard AS, Neary MP, Cella D.
YEAR2007
COLLECTIONPAPERS
FORMATTXT
FILE SIZE24 KB
LICENSECC BY 4.0
RIGHTSCC BY
SOURCEEurope PMC

Source: https://europepmc.org/articles/PMC2248572

Browse the full library · About the Tower of Babel

Full text

The opening of the work, from the library's hosted text:

Estimation of minimally important differences in EQ-5D utility and VAS scores in cancer By A Simon Pickard, Maureen P Neary, David Cella Published in: Health and Quality of Life Outcomes DOI: 10.1186/1477-7525-5-70 ABSTRACT Background Understanding what constitutes an important difference on a HRQL measure is critical to its interpretation. The aim of this study was to provide a range of estimates of minimally important differences (MIDs) in EQ-5D scores in cancer and to determine if estimates are comparable in lung cancer. Methods A retrospective analysis was conducted on cross-sectional data collected from 534 cancer patients, 50 of whom were lung cancer patients. A range of minimally important differences (MIDs) in EQ-5D index-based utility (UK and US) scores and VAS scores were estimated using both anchor-based and distribution-based (1/2 standard deviation and standard error of the measure) approaches. Groups were anchored using Eastern Cooperative Oncology Group performance status (PS) ratings and FACT-G total score-based quintiles. Results For UK-utility scores, MID estimates based on PS ranged from 0.10 to 0.12 both for all cancers and for lung cancer subgroup. Using FACT-G quintiles, MIDs were 0.09 to 0.10 for all cancers, and 0.07 to 0.08 for lung cancer. For US-utility scores, MIDs ranged from 0.07 to 0.09 grouped by PS for all cancers and for lung cancer; when based on FACT-G quintiles, MIDs were 0.06 to 0.07 in all cancers and 0.05 to 0.06 in lung cancer. MIDs for VAS scores were similar for lung and all cancers, ranging from 8 to 12 (PS) and 7 to 10 (FACT-G quintiles). Discussion Important differences in EQ-5D utility and VAS scores were similar for all cancers and lung cancer, with the lower end of the range of estimates closer to the MID, i.e. 0.08 for UK-index scores, 0.06 for US-index scores, and 0.07 for VAS scores. BACKGROUND It is common, if not usual practice, to include health-related quality of life (HRQL) measures in clinical trials in oncology. To justify the cost of new cancer drugs, decision-makers need to determine not only whether a drug has a statistically significant impact on survival and/or HRQL, but they also need to evaluate whether the improvement is meaningful. This is particularly important in lung cancer, where aggressive new therapies are being brought to market. In addition to the use of cancer-specific measures such as European Organization for Research and Treatment of Cancer-QLQ-C30 (EORTC QLQ-C30) [1,2]and the Functional Assessment of Chronic Illness Therapy (FACIT) measurement system [3], clinical trials in oncology are increasingly incorporating generic preference-based measures such as EQ-5D. EQ-5D is an indirect measure of utility for health that generates an index-based summary score based upon societal preference weights [4]. Utility scores enable comparisons of burden of disease across conditions and the calculation of quality-adjusted life-years (QALYs), an outcome used to compare the cost effectiveness of health care technologies. A major challenge in HRQL measurement is the interpretation of scores, particularly with respect to defining what constitutes a minimally important difference (MID). The MID has been defined as the smallest change in a PRO measure that is perceived by patients as beneficial or that would result in a change in treatment [5]. Approaches to estimation of MIDs have been classified as either distribution-based or anchor-based [6]. Anchor-based approaches compare changes seen in an individual's HRQL to an external criterion, such as a clinical measure or using a patient rated global change question. Problematically, no single anchor represents a gold standard and no approach is ideal. Norman et al (1997) found that retrospective global ratings of change have questionable ability to yield information of treatment effects [7]. Alternatively, distribution-based approaches rely on the distribution of scores and are computed using variations on effect size [8]. The main disadvantage to distribution-based techniques is that they do not provide insight into the importance of the difference [9]. Often both approaches are combined, with anchored-based HRQL changes initially framed in terms of the individual are then further analyzed as a group using distribution-based methods [10-15]. While MIDs have been estimated for EQ-5D index-based scores for some conditions [16], empiric work has not been performed in cancer. Additionally, it is not clear if lung cancer has a different range of MID estimates. Thus, the aim of this study was to provide a range of estimates for meaningful difference in EQ-5D scores in cancer and to determine if MIDs for lung cancer are different from all cancers. METHODS Study design A retrospective analysis was conducted on cross-sectional data collected from 534 cancer patients with eleven types of cancer who participated in a validation study of cancer symptoms scales [17]. Participants had advanced (stage 3 or 4) cancer of the bladder, brain, breast (females patients only), colon/rectum, head/neck, liver/pancreas, kidney, lung, lymphoma, ovary (females patients only), and prostate (males patients only). All patients had received at least 2 cycles of chemotherapy, or if chemotherapy was non-cyclical, had been receiving it for at least 1 month. Efforts were made to recruit 50 patients for each type of cancer, with approximately equal proportions of male and female patients for the non-gender specific types of neoplasm. This dataset included 50 patients lung cancer patients, and between 50 and 52 patients with all other types of cancer except bladder cancer (n = 31). The patients were recruited from six sites within the National Cancer Coalition Network (NCCN) and the Cancer Health Alliance of Metropolitan Chicago (CHAMC). The NCCN is a not for profit, tax-exempt corporation that is an alliance of National Cancer Institute (NCI) approved comprehensive cancer centers. The CHAMC organizations provide social, emotional and informational support services to cancer patients free of charge. These organizations are not affiliated with a medical center or university, and each CHAMC agency serves different geographical and socio-demographic cancer patient populations. All patients who completed the questionnaires consented to participate in the study. Institutional review board approval was obtained for secondary data analysis (University of Illinois at Chicago research protocol #2006-0891). Measures Patients completed several questionnaires, including the EQ-5D and the Functional Assessment of Cancer Therapy (FACT). The EQ-5D descriptive system consists of 5 dimensions: Mobility, Self-Care, Usual Activities, Pain/Discomfort, and Anxiety/Depression, each with 3 levels (e.g. no problems, moderate problems, extreme problems) [18]. Index-based summary scores were calculated based on 2 different algorithms using societal preference developed from general population-based valuation studies in the United Kingdom [19] and the USA [20]. The index-based score is typically interpreted along a continuum where 1 represents best possible health and 0 represents dead, with some health states being worse than dead (<0). In addition to the self-classifier, respondents rate their health today using a 20 centimeter visual analogue scale (VAS) that ranges from 0 (worst imaginable health state) to 100 (best imaginable health state). Participants also completed the Functional Assessment of Cancer Therapy (FACT) quality of life questionnaire using a version specific to their tumor type. The general subscales common to all versions (FACT-G) include physical well-being (PWB), social/family well-being (SFWB), emotional well-being (EWB), and functional well-being (FWB). The FACT-G total score (FACT-G Total) is based on 26 summed items (responses 0 to 4) from the PWB (7 items), FWB (7 items), SFWB (6 items), and EWB (6 items). Higher scores represent better quality of life.

Read the complete text